SCHEMBL25242946

SCHEMBL25242946

O=C1NC(=O)/C(=C/c2ccnc(-c3ccc(OC(F)(F)F)cc3)c2)S1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIM1 P11309 9/20 0.70
▸ PIM2 Q9P1W9 7/20 0.70
▸ PIP4K2A P48426 1/20 0.53
▸ SCN9A Q15858 1/20 0.52
▸ CISD1 Q9NZ45 4/20 0.50
▸ TTR P02766 1/20 0.50
▸ NR1H4 Q96RI1 1/20 0.50
▸ NPC1 O15118 3/20 0.49
▸ RAB9A P51151 3/20 0.49
▸ PIK3CA P42336 3/20 0.49
▸ PIK3CG P48736 3/20 0.49
▸ PIK3CD O00329 2/20 0.49
▸ CSNK2A2 P19784 2/20 0.49
▸ PIK3CB P42338 2/20 0.49
▸ MTOR P42345 2/20 0.49
▸ CLK1 P49759 2/20 0.49
▸ DYRK1A Q13627 2/20 0.49
▸ MAOB P27338 1/20 0.49
▸ CSNK2B P67870 1/20 0.49
▸ CSNK2A1 P68400 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25289662 1.00 PIM1 (0.70) PIM1PIM2PIP4K2ASCN9ACISD1
SCHEMBL25288697 0.85 PIM1 (0.67) PIM1PIM2CISD1TTRNR1H4
SCHEMBL25241166 0.85 PIM1 (0.67) PIM1PIM2CISD1NPC1RAB9A
SCHEMBL25283721 0.85 PIM1 (0.67) PIM1PIM2CISD1NPC1RAB9A
SCHEMBL25244787 0.85 PIM1 (0.67) PIM1PIM2CISD1TTRNR1H4
SCHEMBL25287167 0.84 PIM1 (0.73) PIM1PIM2PIP4K2ACISD1NR1H4
SCHEMBL25287166 0.84 PIM1 (0.73) PIM1PIM2PIP4K2ACISD1NR1H4
SCHEMBL2541054 0.83 PIM1 (1.00) PIM1PIM2SCN9ACISD1TTR
SCHEMBL2541053 0.83 PIM1 (1.00) PIM1PIM2SCN9ACISD1TTR
SCHEMBL2541051 0.83 PIM1 (1.00) PIM1PIM2SCN9ACISD1TTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066347-A1 SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME MEDIFIC, INC. (KR) 2025-02-27 — — US claimed
EP-4455143-A1 SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME Medific, Inc. (KR) 2024-10-30 — — EP claimed
CN-118591539-A Substituted thiazolidinedione derivative compounds and pharmaceutical composition for preventing or treating cancer comprising the same (株)美迪菲 2024-09-03 — — CN claimed
WO-2023121184-A1 SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME (주)메디픽 2023-06-29 — — WO claimed
US-20250066347-A1 SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME MEDIFIC, INC. (KR) 2025-02-27 — — US disclosed
EP-4455143-A1 SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME Medific, Inc. (KR) 2024-10-30 — — EP disclosed
CN-118591539-A Substituted thiazolidinedione derivative compounds and pharmaceutical composition for preventing or treating cancer comprising the same (株)美迪菲 2024-09-03 — — CN disclosed
WO-2023121184-A1 SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME (주)메디픽 2023-06-29 — — WO disclosed
WO-2023121184-A1 SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME (주)메디픽 2023-06-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066347-A1 SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME SREBF1, SREBF2, SP1 PIM1 922/4885PIM2 1740/4885PIP4K2A 2742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback